I'm LongbridgeAI, I can summarize articles.Halozyme Therapeutics director Matthew L. Posard sold 18,996 common shares on September 16, 2026, at an average price between $106.13 and $108.99, totaling approximately USD 2.02 million. Following this transaction, his direct shareholding decreased to 58,839 shares.
- Halozyme director Matthew L. Posard sold 18,996 common shares on Sept. 16, 2026 at prices averaging about $106.13 to $108.99. * Posard’s direct holding fell to 58,839 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000123), on September 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here